Cromwell Holdings LLC Sells 41 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Cromwell Holdings LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 789 shares of the pharmaceutical company’s stock after selling 41 shares during the quarter. Cromwell Holdings LLC’s holdings in Vertex Pharmaceuticals were worth $318,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Whittier Trust Co. lifted its position in Vertex Pharmaceuticals by 5.9% during the third quarter. Whittier Trust Co. now owns 1,533 shares of the pharmaceutical company’s stock valued at $713,000 after acquiring an additional 86 shares during the last quarter. Foundations Investment Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 11.3% during the third quarter. Foundations Investment Advisors LLC now owns 849 shares of the pharmaceutical company’s stock worth $395,000 after purchasing an additional 86 shares in the last quarter. Eastern Bank purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at $805,000. Stanley Laman Group Ltd. acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth $203,000. Finally, BLB&B Advisors LLC grew its stake in Vertex Pharmaceuticals by 23.4% during the 3rd quarter. BLB&B Advisors LLC now owns 527 shares of the pharmaceutical company’s stock worth $245,000 after buying an additional 100 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. decreased their price target on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a research note on Monday, December 23rd. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 11th. StockNews.com cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. Jefferies Financial Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price target for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $505.61.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $480.33 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock’s 50 day simple moving average is $435.64 and its two-hundred day simple moving average is $460.65. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.58 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.